Christine Årdal
YOU?
Author Swipe
View article: Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements
Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements Open
Tarang Sharma and colleagues argue for increased collaboration across public and private sectors—internationally and with patients—in drug assessment and managed entry agreements to support equitable and sustainable access to costly medici…
View article: Sustainable pharmaceutical procurement: Environmental tendering criteria for better or worse?
Sustainable pharmaceutical procurement: Environmental tendering criteria for better or worse? Open
View article: Resilience and Adaptability in Paracetamol Supply Chains: A Systems Perspective on COVID-19 Challenges and Responses in Ethiopia
Resilience and Adaptability in Paracetamol Supply Chains: A Systems Perspective on COVID-19 Challenges and Responses in Ethiopia Open
Background: The COVID-19 pandemic exposed vulnerabilities in global supply chains, including those for essential medicines like paracetamol. This study aimed to assess the resilience and adaptability of Ethiopia’s paracetamol supply chain …
View article: Fragmented markets for older antibiotics and child formulations, Denmark, Norway, Sweden
Fragmented markets for older antibiotics and child formulations, Denmark, Norway, Sweden Open
Antibiotic resistance is one of the most urgent threats to public health. The development of antibiotic resistance can be reduced by the use of narrow-spectrum antibiotics that target specific bacteria, meaning that fewer non-harmful bacte…
View article: Policy options for sustainable access to off-patent antibiotics in Europe
Policy options for sustainable access to off-patent antibiotics in Europe Open
Securing sustainable access to existing antibiotics optimises agent choice for individual treatments and is crucial to curb antibiotic resistance. Access to antibiotics is often restricted in many countries, due to general market unavailab…
View article: The multifaceted nature of lack of access to antibiotics: types of shortage and specific causes, consequences, and solutions
The multifaceted nature of lack of access to antibiotics: types of shortage and specific causes, consequences, and solutions Open
It is essential to understand the type of unavailability at hand because no single solution can address all types. For instance, stockpiling addresses short-term shortages, but not long-term ones or deregistrations. However, supply chain t…
View article: High-Throughput Discovery of Synthetic Siderophores for Trojan Horse Antibiotics
High-Throughput Discovery of Synthetic Siderophores for Trojan Horse Antibiotics Open
To cause infection, bacterial pathogens must overcome host immune factors and barriers to nutrient acquisition. Reproducing these aspects of host physiology in vitro has shown great promise for antibacterial drug discovery. When used as a …
View article: Thank you to reviewers 2023
Thank you to reviewers 2023 Open
View article: Availability of essential, generic medicines before and during COVID-19 at selected public pharmaceutical supply agencies in Ethiopia: a comparative cross-sectional study
Availability of essential, generic medicines before and during COVID-19 at selected public pharmaceutical supply agencies in Ethiopia: a comparative cross-sectional study Open
Objectives Lockdowns and border closures impacted medicine availability during the COVID-19 pandemic. This study aimed to assess the availability of essential, generic medicines for chronic diseases at public pharmaceutical supply agencies…
View article: Sustainable Pharmaceutical Procurement: Innovative Tendering with Triple-Bottom Line Benefits
Sustainable Pharmaceutical Procurement: Innovative Tendering with Triple-Bottom Line Benefits Open
View article: The knock-on effects of COVID-19 pandemic on the supply and availability of generic medicines in Ethiopia: mixed methods study
The knock-on effects of COVID-19 pandemic on the supply and availability of generic medicines in Ethiopia: mixed methods study Open
View article: Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation
Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation Open
View article: Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?
Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? Open
View article: Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020
Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020 Open
Background Inaccessibility of medicines in low- and middle-income countries is a frequent challenge. Yet it is typically assumed that high-income countries have complete access to the full arsenal of medicines. This study tests this assump…
View article: National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation
National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation Open
Prominent reports have assessed the challenges to antibiotic innovation and recommended implementing “pull” incentives, i.e., mechanisms that give increased and predictable revenues for important, marketed antibiotics. We set out to unders…
View article: The effect of generic market entry on antibiotic prescriptions in the United States
The effect of generic market entry on antibiotic prescriptions in the United States Open
View article: Supply chain transparency and the availability of essential medicines
Supply chain transparency and the availability of essential medicines Open
View article: Adapting environmental surveillance for polio to the need to track antimicrobial resistance
Adapting environmental surveillance for polio to the need to track antimicrobial resistance Open
View article: Patient Access in Fourteen High-Income Countries to New Antibacterials Approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020
Patient Access in Fourteen High-Income Countries to New Antibacterials Approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020 Open
View article: A one health framework to estimate the cost of antimicrobial resistance
A one health framework to estimate the cost of antimicrobial resistance Open
View article: A One Health framework to estimate the cost of antimicrobial resistance.
A One Health framework to estimate the cost of antimicrobial resistance. Open
Objectives/Purpose The costs attributable to antimicrobial resistance (AMR) remain theoretical and largely unspecified. Current figures fail to capture the full health and economic burden caused by AMR across human, animal, and environment…
View article: Infection prevention and control research priorities: what do we need to combat healthcare-associated infections and antimicrobial resistance? Results of a narrative literature review and survey analysis
Infection prevention and control research priorities: what do we need to combat healthcare-associated infections and antimicrobial resistance? Results of a narrative literature review and survey analysis Open
View article: A One Health Framework to Estimate Costs of Antimicrobial Resistance
A One Health Framework to Estimate Costs of Antimicrobial Resistance Open
Objectives/PurposeThe costs attributable to antimicrobial resistance (AMR) across human, animal, and environmental health remain theoretical and largely unspecified. Current figures fail to capture the full health and economic burden cause…
View article: A case study on <i>Staphylococcus aureus</i> bacteraemia: available treatment options, antibiotic R&D and responsible antibiotic-use strategies
A case study on <i>Staphylococcus aureus</i> bacteraemia: available treatment options, antibiotic R&D and responsible antibiotic-use strategies Open
Objectives This case study addresses: (i) antibiotic treatment options for Staphylococcus aureus bacteraemia (SAB), for both empirical and targeted therapy; (ii) the current status of and priorities for the antibiotic pipeline to ensure ac…
Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe Open
View article: Industrial perceptions of medicines regulatory harmonization in the East African Community
Industrial perceptions of medicines regulatory harmonization in the East African Community Open
Pharmaceutical companies agree that medicines regulatory harmonization is the way forward. However, regulatory medicines harmonization must actually result in quicker access to the harmonized markets for quality-assured medicines. At this …
View article: Peer Review #2 of "Crowdsourcing in medical research: concepts and applications (v0.2)"
Peer Review #2 of "Crowdsourcing in medical research: concepts and applications (v0.2)" Open
Crowdsourcing shifts medical research from a closed environment to an open collaboration between the public and researchers.We define crowdsourcing as an approach to problem solving which involves an organization having a large group attem…
View article: Peer Review #2 of "Crowdsourcing in medical research: concepts and applications (v0.1)"
Peer Review #2 of "Crowdsourcing in medical research: concepts and applications (v0.1)" Open
Crowdsourcing shifts medical research from a closed environment to an open collaboration between the public and researchers.We define crowdsourcing as an approach to problem solving which involves an organization having a large group attem…
View article: Introduction and geographic availability of new antibiotics approved between 1999 and 2014
Introduction and geographic availability of new antibiotics approved between 1999 and 2014 Open
Our findings show great variation in geographic availability of antibiotics, indicating that availability in multiple regions and country income classes is possible, but rarely seen within a few years of market authorization. Sublicensing …
View article: Ensuring Antibiotic Development, Equitable Availability, and Responsible Use of Effective Antibiotics: Recommendations for Multisectoral Action
Ensuring Antibiotic Development, Equitable Availability, and Responsible Use of Effective Antibiotics: Recommendations for Multisectoral Action Open
Antibiotic resistance is a growing threat to global public health. The World Health Organization's Global Action Plan on Antimicrobial Resistance recommends engaging multisectoral stakeholders to tackle the issue. However, so far, few stud…